StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report issued on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00. The stock has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Featured Stories
- Five stocks we like better than Genocea Biosciences
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- CD Calculator: Certificate of Deposit Calculator
- 3 Penny Stocks Ready to Break Out in 2025
- When to Sell a Stock for Profit or Loss
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.